Investments
31Portfolio Exits
8Latest Lake Bleu Capital News
Nov 5, 2020
Broncus Holding Company , a Hangzhou, China-based global leader in diagnostic and therapeutic technology for lung diseases, closed a Series C round of funding. The round was led by Lake Bleu Capital, with participation from Baidu Capital, Ascendum Capital, CNCB Capital and DCP Capital, along with previous investor Qiming Venture Capital. The funds will be used to further develop markets and technology across lung cancer, emphysema and other important lung diseases. Founded in 2012 and led by CEO Zhan Guowei, Broncus is dedicated to the development of diagnostic and therapeutic technology for lung disease. The company’s primary technology platforms focus on the diagnosis of lung cancer and the treatment of emphysema. Its lung cancer portfolio includes the Archimedes® System, Archimedes® Planner, LungPoint® Virtual Bronchoscopic Navigation (VBN) System, LungPoint® Planner and FleXNeedle®. The Archimedes System has been cleared by the FDA (U.S.), CE (Europe) and NMPA (China) and had broad patent protection globally. The InterVapor System has received the CE Mark. FinSMEs 04/11/2020
Lake Bleu Capital Investments
31 Investments
Lake Bleu Capital has made 31 investments. Their latest investment was in Bangbang Robot as part of their Series B on June 6, 2022.
Lake Bleu Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/30/2022 | Series B | Bangbang Robot | $14.9M | Yes | 2 | |
4/11/2022 | Series A - II | Synthegene | $47.1M | Yes | 1 | |
1/25/2022 | Series D - II | Tongxin Medical | No | 1 | ||
12/31/2021 | Series C | |||||
11/24/2021 | Series C |
Date | 6/30/2022 | 4/11/2022 | 1/25/2022 | 12/31/2021 | 11/24/2021 |
|---|---|---|---|---|---|
Round | Series B | Series A - II | Series D - II | Series C | Series C |
Company | Bangbang Robot | Synthegene | Tongxin Medical | ||
Amount | $14.9M | $47.1M | |||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 2 | 1 | 1 |
Lake Bleu Capital Portfolio Exits
8 Portfolio Exits
Lake Bleu Capital has 8 portfolio exits. Their latest portfolio exit was Ruike Biotechnology on March 31, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
3/31/2022 | IPO | Public | 1 | ||
Date | 3/31/2022 | ||||
|---|---|---|---|---|---|
Exit | IPO | ||||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.